Anti-amyloid monoclonal antibodies

Intervention2 papers1 finding

Outcomes

1

Cognitive decline

downin humans1

1 study

Anti-amyloid monoclonal antibodies decrease cognitive decline in humans.
Reviewin symptomatic Alzheimer's disease
Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change · The Lancet. Neurology · 9 Sep 2026

Latest

2

The Lancet NeurologyReview9 Sep

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change

Alzheimer's disease

MedicinaReview27 Aug

Beyond Amyloid: Systemic and Brain Frailty as Determinants of Response to Anti-Amyloid Therapy in Alzheimer's Disease-A Conceptual Review

Alzheimer's disease